The funding will help support the whole-genome and RNA sequencing of Alzheimer's disease patients to advance biomarker development.
Using omics and other data, researchers performed network analyses that pointed to interactions between human herpesviruses and other Alzheimer's disease risk factors.
The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.
By combining iPSCs, CRISPR gene editing, and transcriptomic approaches, researchers examined the effects of an Alzheimer's disease risk variant on brain cells.
The company plans to test both its current technology and explore novel signatures using samples from Mayo's biobank.
Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
The collaborators aim to show that Cytox' VariaTect SNP profiling array and an associated algorithm can effectively predict the presence of Alzheimer's pathology.
Chromatin immunoprecipitation sequencing showed divergent H4K16ac histone acetylation patterns in brain samples from young, old, and AD-affected individuals.
Funded projects will will take advantage of molecular platforms that enable large-scale, robust, and reproducible analysis of transcriptional, epigenomic, proteomic, and metabolomic states.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.